Bundkirchen A, Brixius K, Schwinger R H G
Labor für Herzmuskelphysiologie und Molekulare Kardiologie, Klinik III für Innere Medizin der Universität zu Köln, Germany.
Pharmazie. 2004 Feb;59(2):83-92.
Beta-Adrenoceptor antagonists in the treatment of chronic heart failure The incidence of chronic heart failure is high in the developed countries (1-4/1000 per year). Treatment of chronic heart failure is a therapeutic challenge. A great improvement in mortality and morbidity of heart failure patients was achieved by the introduction of beta-adrenoceptor blockers in the treatment of chronic heart failure. However only 39% of heart failure patients are treated with a beta-adrenoceptor blocker in Europe. This review outlines pathophysiology of the beta-adrenergic system during human heart failure and its alterations induced by beta-adrenoceptor blockade. Based on the results of large clinical trials, experimental-pharmacological properties of beta-adrenoceptor blockers as well as the main aspects of its clinical use are discussed.
β-肾上腺素能受体拮抗剂在慢性心力衰竭治疗中的应用 发达国家慢性心力衰竭的发病率较高（每年1-4/1000）。慢性心力衰竭的治疗是一项治疗挑战。在慢性心力衰竭治疗中引入β-肾上腺素能受体阻滞剂后，心力衰竭患者的死亡率和发病率有了很大改善。然而，在欧洲，只有39%的心力衰竭患者接受β-肾上腺素能受体阻滞剂治疗。本综述概述了人类心力衰竭期间β-肾上腺素能系统的病理生理学及其由β-肾上腺素能受体阻断引起的改变。基于大型临床试验的结果，讨论了β-肾上腺素能受体阻滞剂的实验药理学特性及其临床应用的主要方面。
